Overview

Gender

male

Investor Type

Investment Partner

Daniel Lynch is a Venture Partner at Third Rock Ventures since May 2013. Daniel joined Third Rock Ventures in 2011 and serves as a Strategic Advisor across their portfolio.

Daniel brings more than 25 years of experience in biotechnology and pharmaceutical companies and has taken active board roles in several of their portfolio companies: Mmember and Chairman of the Board of Directors at Bluebird Bio, Member and Executive Chairman of the Board of Directors at Blueprint Medicines, Member and Chairman of the Board of Directors at Eleven Biotherapeutics.

In addition to his role at Third Rock, Daniel serves as Executive Chairman of the Board of Directors at BIND Therapeutics, Nimbus Discovery and RaNA Therapeutics.

Prior to joining Third Rock, Daniel served as Chief Executive and Chief Financial Officer at ImClone Systems Corp. While at ImClone, he negotiated a major partnership with Bristol-Myers Squibb and led the company through a significant turnaround, helping restore its reputation and secure FDA approval of its novel cancer treatment ERBITUX. Dan has served as Executive Chair or Board Member for a number of private biopharmaceutical companies, including Stromedix until its acquisition by Biogen Idec in February 2012 and Avila Therapeutics Inc. until its acquisition by Celgene Corp. in February 2012.

Earlier in his career, Daniel served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. Daniel served on the board of directors and the audit committee of U.S. Oncology Inc. for five years until December 2010 when it was acquired by McKesson.

Daniel received his B.A. in Mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.

Dan was the fastest swimmer in New England at the age of 10.